Cardiff Oncology, Inc. (CRDF): Total Liabilities
$16.50M
As of 2025-12-31
$10.80M
As of 2026-06-30
+18.8%
3-year compound annual growth
+20.2%
5-year compound annual growth
-3.2%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.50M | +15.8% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $14.24M | +19.7% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $11.90M | +20.8% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $9.85M | +7.9% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $9.13M | +38.9% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $6.57M | +13.7% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $5.78M | +41.3% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $4.09M | -29.3% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $5.78M | -76.1% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $24.18M | +6.3% | 2018-02-26, Balance as of period end |
| 2015-12-31 | $22.74M | +10.7% | 2017-03-15, Balance as of period end |
| 2014-12-31 | $20.55M | +203.8% | 2016-03-10, Balance as of period end |
| 2013-12-31 | $6.76M | -28.8% | 2015-03-12, Balance as of period end |
| 2012-12-31 | $9.50M | +80.2% | 2014-03-17, Balance as of period end |
| 2011-12-31 | $5.27M | n/a | 2013-04-01, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $16.50M | +15.8% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $19.84M | +13.7% |
| Prokidney Corp. (PROK) | 2025-12-31 | $34.78M | -11.8% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $138.49M | +193.5% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $50.77M | -50.2% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $113.26M | -40.6% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $34.99M | -64.7% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $2.16M | -21.9% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $8.48M | +104.1% |
Compare CRDF, IMA, PROK, INBX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗